Canakinumab can prove worth in children with Systemic Juvenile Idiopathic ArthritisA new interleukin-1 (IL-1)-beta blocking monoclonal antibody, Canakinumab (ACZ885), was recently found to be an effective option to encourage effectiveness besides being well tolerated in children with sJIA (systemic juvenile idiopathic arthritis).

This finding was disclosed in a phase II study presented at PReS 2009, a joint congress with the 2009 Congress of the European League against Rheumatism (EULAR) in Copenhagen, Denmark.

JIA is considered to be one of the most common chronic inflammatory diseases of childhood that affects approximately 1 in every 1,000 children. sJIA is the most severe subtype of JIA.